Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Persistent diarrhea in travelers

H L DuPont1, E G Capsuto

  • 1University of Texas Health Science Center, Houston, USA.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|January 1, 1996
PubMed
Summary

Persistent traveler's diarrhea affects 3% of travelers. Initial evaluation involves stool samples, followed by empirical antimicrobial or antiprotozoal therapy for refractory cases. Symptomatic treatment offers reassurance for persistent symptoms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fecal calprotectin and fecal indole predict outcome of fecal microbiota transplantation in subjects with recurrent Clostridium difficile infection.

Anaerobe·2019
Same author

Etiology of travellers' diarrhea.

Journal of travel medicine·2017
Same author

Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridum difficile infection - fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy.

Alimentary pharmacology & therapeutics·2017
Same author

Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study.

The Journal of hospital infection·2016
Same author

Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.

Alimentary pharmacology & therapeutics·2015
Same author

Review article: the antimicrobial effects of rifaximin on the gut microbiota.

Alimentary pharmacology & therapeutics·2015

Area of Science:

  • Gastroenterology
  • Infectious Diseases
  • Travel Medicine

Background:

  • Traveler's diarrhea (TD) is common, with most cases resolving with standard treatment.
  • A subset of patients (approximately 3%) develop persistent diarrhea lasting 14 days or longer.
  • Managing persistent TD requires a structured diagnostic and therapeutic approach.

Purpose of the Study:

  • To outline an effective management strategy for persistent traveler's diarrhea.
  • To guide clinicians in the evaluation and treatment of prolonged diarrheal illness in travelers.

Main Methods:

  • Initial diagnostic step: collection of three stool samples for pathogen examination.
  • Empirical treatment: antimicrobial therapy for bacterial enteropathogens if not previously administered.
  • Further management: antiprotozoal therapy, endoscopic evaluation, and symptomatic treatment for refractory cases.

Main Results:

  • Early identification of pathogens through stool samples is crucial.
  • Empirical antimicrobial and antiprotozoal therapies are key steps for non-responsive cases.
  • Endoscopic evaluation is indicated for persistent diarrhea unresponsive to empirical treatments.
  • Symptomatic treatment and reassurance are recommended for individuals with continued diarrhea after comprehensive workup, with a good prognosis.

Conclusions:

  • Persistent traveler's diarrhea necessitates a stepwise diagnostic and therapeutic approach.
  • Empirical therapies and endoscopic evaluation play vital roles in managing refractory cases.
  • Most patients with persistent TD, even those requiring symptomatic treatment, have a favorable long-term outlook.

Related Experiment Videos